• 1. Immunotherapy must be discontinued in all patients who experience irAEs, regardless of grade.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%

• 2. This classification of irAEs is the most common and often has the earliest onset of symptoms.
• Your Colleagues Responded
• A. Cardiovascular Toxicities

  0%
• B. Renal Toxicities

  0%
• C. Dermatologic Toxicities

  0%
• D. Pulmonary Toxicities

  0%

• 3. Patients report higher incidence of ______________ with anti-CTLA therapy compared with ____________ that is more often associated with anti-PD-1/L1 therapy.
• Your Colleagues Responded
• A. Pneumonitis; encephalitis

  0%
• B. Hepatitis, colitis

  0%
• C. Thyroid function; colitis

  0%
• D. Colitis; thyroid dysfunction

  0%

• 4. Saliva substitutes and/or artificial tears are often used in the treatment of _______________ a rheumatologic irAE.
• Your Colleagues Responded
• A. Inflammatory Arthritis

  0%
• B. Myositis

  0%
• C. Sicca Syndrome

  0%
• D. Myasthenia Gravis

  0%

• 5. ICI therapy can affect the heart in both _____________ and ___________ manner.
• Your Colleagues Responded
• A. Positive and negative manner

  0%
• B. Inflammatory and non-inflammatory

  0%
• C. Muscular and non-muscular

  0%
• D. Constrictive and non-constrictive

  0%

• 6. Most patients receiving immunotherapy only experience a single irAE during their treatment course.
• Your Colleagues Responded
• A. True

  0%
• B. False

  0%